Bio-Europe Conference, page-2

>Zolpimist is on the table having FDA approval. This has to be attractive to companies outside the US. (Suda does not have rights to the US >market)

I wouldnt rule out SUDA bringing in Amherst on a joint sale of worldwide rights, carving up the proceeds proportionately. This would be more attractive to global pharma, the whole being more than the sum of the parts. They kind of did something similar with London Pharma on Artimist in regards to broadening the rights from Africa to worldwide and adult, so there is precedent in this kind of deal. Obviously ECR and parent Valeant's current arrangement with Amherst may need consideration in this case.